Plasminogen activator inhibitor-1 regulates macrophage-dependent postoperative adhesion by enhancing EGF-HER1 signaling in mice

FASEB J. 2017 Jun;31(6):2625-2637. doi: 10.1096/fj.201600871RR. Epub 2017 Mar 7.

Abstract

Adhesive small bowel obstruction remains a common problem for surgeons. After surgery, platelet aggregation contributes to coagulation cascade and fibrin clot formation. With clotting, fibrin degradation is simultaneously enhanced, driven by tissue plasminogen activator-mediated cleavage of plasminogen to form plasmin. The aim of this study was to investigate the cellular events and proteolytic responses that surround plasminogen activator inhibitor (PAI-1; Serpine1) inhibition of postoperative adhesion. Peritoneal adhesion was induced by gauze deposition in the abdominal cavity in C57BL/6 mice and those that were deficient in fibrinolytic factors, such as Plat-/- and Serpine1-/- In addition, C57BL/6 mice were treated with the novel PAI-1 inhibitor, TM5275. Some animals were treated with clodronate to deplete macrophages. Epidermal growth factor (EGF) experiments were performed to understand the role of macrophages and how EGF contributes to adhesion. In the early phase of adhesive small bowel obstruction, increased PAI-1 activity was observed in the peritoneal cavity. Genetic and pharmacologic PAI-1 inhibition prevented progression of adhesion and increased circulating plasmin. Whereas Serpine1-/- mice showed intra-abdominal bleeding, mice that were treated with TM5275 did not. Mechanistically, PAI-1, in combination with tissue plasminogen activator, served as a chemoattractant for macrophages that, in turn, secreted EGF and up-regulated the receptor, HER1, on peritoneal mesothelial cells, which led to PAI-1 secretion, further fueling the vicious cycle of impaired fibrinolysis at the adhesive site. Controlled inhibition of PAI-1 not only enhanced activation of the fibrinolytic system, but also prevented recruitment of EGF-secreting macrophages. Pharmacologic PAI-1 inhibition ameliorated adhesion formation in a macrophage-dependent manner.-Honjo, K., Munakata, S., Tashiro, Y., Salama, Y., Shimazu, H., Eiamboonsert, S., Dhahri, D., Ichimura, A., Dan, T., Miyata, T., Takeda, K., Sakamoto, K., Hattori, K., Heissig, B. Plasminogen activator inhibitor-1 regulates macrophage-dependent postoperative adhesion by enhancing EGF-HER1 signaling in mice.

Keywords: PAI-1; epidermal growth factor; mesothelial cell; plasminogen activator; small bowel obstruction.

MeSH terms

  • Animals
  • CD11b Antigen
  • Cell Migration Assays
  • Cell Movement / drug effects
  • Cetuximab / pharmacology
  • Epidermal Growth Factor
  • ErbB Receptors / genetics
  • ErbB Receptors / metabolism*
  • Gene Expression Regulation / physiology
  • Macrophages / physiology*
  • Mice
  • Mice, Inbred C57BL
  • Piperazines / therapeutic use*
  • Postoperative Complications / prevention & control
  • RAW 264.7 Cells
  • Serpin E2 / antagonists & inhibitors*
  • Serpin E2 / genetics
  • Serpin E2 / metabolism
  • Signal Transduction
  • Tissue Adhesions / metabolism
  • Tissue Adhesions / pathology*
  • Tissue Plasminogen Activator / genetics
  • Tissue Plasminogen Activator / metabolism
  • para-Aminobenzoates / therapeutic use*

Substances

  • 5-chloro-2-(((2-(4-(diphenylmethyl)piperazin-1-yl)-2-oxoethoxy)acetyl)amino)benzoate
  • CD11b Antigen
  • Piperazines
  • Serpin E2
  • Serpine2 protein, mouse
  • para-Aminobenzoates
  • Epidermal Growth Factor
  • ErbB Receptors
  • Tissue Plasminogen Activator
  • Cetuximab